RT Journal Article
SR Electronic
T1 Fall 2021 Resurgence and COVID-19 Seroprevalence in Canada Modelling waning and boosting COVID-19 immunity in Canada A Canadian Immunization Research Network Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.17.21262188
DO 10.1101/2021.08.17.21262188
A1 Dick, David W.
A1 Childs, Lauren
A1 Feng, Zhilan
A1 Li, Jing
A1 Röst, Gergely
A1 Buckeridge, David L
A1 Ogden, Nick H
A1 Heffernan, Jane M
YR 2021
UL http://medrxiv.org/content/early/2021/08/24/2021.08.17.21262188.abstract
AB There is a threat of COVID-19 resurgence in Fall 2021 in Canada. To understand the probability and severity of this threat, quantification of the level of immunity/protection of the population is required. We use an age-structured model including infection, vaccination and waning immunity to estimate the distribution of immunity to COVID-19 in the Canadian population. By late Summer 2021, coinciding with the end of the vaccination program, we estimate that 60 − 80% of the Canadian population will have some immunity to COVID-19. Model results show that this level of immunity is not sufficient to stave off a Fall 2021 resurgence. The timing and severity of a resurgence, however, varies in magnitude given multiple factors: relaxation of non-pharmaceutical interventions such as social distancing, the rate of waning immunity, the transmissibility of variants of concern, and the protective characteristics of the vaccines against infection and severe disease. To prevent large-scale resurgence, booster vaccination and/or re-introduction of public health mitigation may be needed.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work is supported by NSERC and the Canadian Immunization Research Network.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThere is no data used in this study.